<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Aditxt Inc. — News on 6ix</title>
<link>https://6ix.com/company/aditxt-inc</link>
<description>Latest news and press releases for Aditxt Inc. on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Mon, 20 Apr 2026 12:15:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/aditxt-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo683542bf78dffbe2df0e16d2.webp</url>
<title>Aditxt Inc.</title>
<link>https://6ix.com/company/aditxt-inc</link>
</image>
<item>
<title>Dana-Farber Cancer Institute Study Demonstrates Predictive Value of Ignite Proteomics’ RPPA Platform for T-DXd (Enhertu®) Therapy in Metastatic Breast Cancer Patients</title>
<link>https://6ix.com/company/aditxt-inc/news/dana-farber-cancer-institute-study-demonstrates-predictive-value-of-ignite-proteomics-rppa-platform-for-t-dxd-enhertur-therapy-in-metastatic-breast-cancer-patients</link>
<guid isPermaLink="true">https://6ix.com/company/aditxt-inc/news/dana-farber-cancer-institute-study-demonstrates-predictive-value-of-ignite-proteomics-rppa-platform-for-t-dxd-enhertur-therapy-in-metastatic-breast-cancer-patients</guid>
<pubDate>Mon, 20 Apr 2026 12:15:00 GMT</pubDate>
<description>MOUNTAIN VIEW, Calif., April 20, 2026--Aditxt, Inc. (Nasdaq: ADTX) ("Aditxt" or the "Company"), a social innovation platform accelerating promising health innovations, today announced that its precision oncology subsidiary, Ignite Proteomics, LLC ("Ignite" or "Ignite Proteomics"), has been featured in a peer-reviewed study published online ahead of print in npj Precision Oncology, a Nature journal. The study, led by investigators at Dana-Farber Cancer Institute, evaluated outcomes among patients</description>
</item>
<item>
<title>Aditxt Subsidiary Ignite Proteomics Appoints Public Company Veteran Jeff Busch as Chief Executive Officer</title>
<link>https://6ix.com/company/aditxt-inc/news/aditxt-subsidiary-ignite-proteomics-appoints-public-company-veteran-jeff-busch-as-chief-executive-officer</link>
<guid isPermaLink="true">https://6ix.com/company/aditxt-inc/news/aditxt-subsidiary-ignite-proteomics-appoints-public-company-veteran-jeff-busch-as-chief-executive-officer</guid>
<pubDate>Thu, 19 Mar 2026 04:00:00 GMT</pubDate>
<description>Busch brings public company leadership and capital markets experience to support Ignite’s next phase of growth MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--</description>
</item>
<item>
<title>Aditxt Acquires Ignite Proteomics to Address a Critical Challenge in Cancer Care: Optimizing Therapy Selection</title>
<link>https://6ix.com/company/aditxt-inc/news/aditxt-acquires-ignite-proteomics-to-address-a-critical-challenge-in-cancer-care-optimizing-therapy-selection</link>
<guid isPermaLink="true">https://6ix.com/company/aditxt-inc/news/aditxt-acquires-ignite-proteomics-to-address-a-critical-challenge-in-cancer-care-optimizing-therapy-selection</guid>
<pubDate>Fri, 13 Mar 2026 12:15:00 GMT</pubDate>
<description>MOUNTAIN VIEW, Calif., March 13, 2026--Aditxt, Inc. (NASDAQ: ADTX) ("Aditxt" or the "Company"), a social innovation platform accelerating promising health innovations, today announced the acquisition of Ignite Proteomics, LLC ("Ignite"), a commercial-stage precision oncology company focused on addressing a critical challenge in cancer care: optimizing therapy selection. Ignite’s functional proteomics platform has demonstrated the ability to identify cancer therapy responses that may not be captu</description>
</item>
<item>
<title>Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-8 Reverse Stock Split Effective at the Open of Trading on March 9, 2026</title>
<link>https://6ix.com/company/aditxt-inc/news/aditxt-inc-nasdaq-adtx-announces-1-for-8-reverse-stock-split-effective-at-the-open-of-trading-on-march-9-2026-34</link>
<guid isPermaLink="true">https://6ix.com/company/aditxt-inc/news/aditxt-inc-nasdaq-adtx-announces-1-for-8-reverse-stock-split-effective-at-the-open-of-trading-on-march-9-2026-34</guid>
<pubDate>Thu, 05 Mar 2026 05:00:00 GMT</pubDate>
<description>MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)-- Aditxt, Inc. (Nasdaq: ADTX) (“Aditxt” or the “Company”), a social innovation platform accelerating promising health</description>
</item>
<item>
<title>Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-113 Reverse Stock Split Effective at the Open of Trading on November 3, 2025</title>
<link>https://6ix.com/company/aditxt-inc/news/aditxt-inc-nasdaq-adtx-announces-203000966</link>
<guid isPermaLink="true">https://6ix.com/company/aditxt-inc/news/aditxt-inc-nasdaq-adtx-announces-203000966</guid>
<pubDate>Wed, 29 Oct 2025 20:30:00 GMT</pubDate>
<description>MOUNTAIN VIEW, Calif., October 29, 2025--Aditxt, Inc. (NASDAQ: ADTX) ("Aditxt" or the "Company"), a social innovation platform accelerating promising health innovations, announced today that it will effect a 1-for-113 reverse split of its common stock. Commencing with the opening of trading on the Nasdaq Capital Market on November 3, 2025, the Company’s common stock will trade on a post-split basis under the same symbol ADTX. The reverse stock split was approved by the Company’s stockholders at</description>
</item>
<item>
<title>Aditxt Subsidiary Pearsanta Begins Enrollment in First Human Study of Blood-Based Diagnostic for Endometriosis, a Condition Affecting 190 Million Women Worldwide and Representing a $1.45 Billion Global Market</title>
<link>https://6ix.com/company/aditxt-inc/news/aditxt-subsidiary-pearsanta-begins-enrollment-123000640</link>
<guid isPermaLink="true">https://6ix.com/company/aditxt-inc/news/aditxt-subsidiary-pearsanta-begins-enrollment-123000640</guid>
<pubDate>Mon, 27 Oct 2025 12:30:00 GMT</pubDate>
<description>MOUNTAIN VIEW, Calif., October 27, 2025--Aditxt, Inc. (Nasdaq: ADTX) ("Aditxt" or the "Company"), a social innovation platform accelerating promising health innovations, today announced that its subsidiary, Pearsanta, Inc. ("Pearsanta"), has begun enrollment in their prospective clinical study evaluating the Mitomic® Endometriosis Test (MET™), a novel blood-based diagnostic designed to aid in the early detection of endometriosis.</description>
</item>
<item>
<title>Aditxt’s Subsidiary Adimune Highlights Its Approach to Reprogramming the Immune System Through DNA Instructions, Now with 96 Granted and 22 Pending Patents Targeting Autoimmunity Market Estimated at Over $160 Billion by 2030</title>
<link>https://6ix.com/company/aditxt-inc/news/aditxt-subsidiary-adimune-highlights-approach-131500900</link>
<guid isPermaLink="true">https://6ix.com/company/aditxt-inc/news/aditxt-subsidiary-adimune-highlights-approach-131500900</guid>
<pubDate>Mon, 25 Aug 2025 13:15:00 GMT</pubDate>
<description>MOUNTAIN VIEW, Calif., August 25, 2025--Aditxt, Inc. (NASDAQ: ADTX) ("Aditxt", or the "Company"), a social innovation platform accelerating promising health innovations, today announced an update on its wholly owned subsidiary Adimune, Inc. ("Adimune"), which is pioneering a DNA-based therapeutic platform designed to reprogram the immune system. Adimune’s intellectual property portfolio now includes 96 granted and 22 pending patents that are owned or exclusively licensed by Aditxt, supporting th</description>
</item>
<item>
<title>Evofem Reports Positive Financial Results for Second Quarter of 2025, Provides Business Update</title>
<link>https://6ix.com/company/aditxt-inc/news/evofem-reports-positive-financial-results-for-second-quarter-of-2025-provides-business-update-1</link>
<guid isPermaLink="true">https://6ix.com/company/aditxt-inc/news/evofem-reports-positive-financial-results-for-second-quarter-of-2025-provides-business-update-1</guid>
<pubDate>Thu, 14 Aug 2025 12:46:00 GMT</pubDate>
<description>Women's health innovator Evofem Biosciences, Inc. (Evofem or the Company) (OTCID: EVFM), today announced financial results for the three- and six-month periods ended June 30, 2025 and provided a business update. Notable developments since April 1st include:</description>
</item>
<item>
<title>Aditxt’s Subsidiary, Pearsanta, Inc. Engages Spartan Capital as Lead Underwriter for its Planned IPO Intending to Drive Clinical Validation and Commercial Rollout of Its Mitomic™ Platform Technology for Early Detection of Cancers and Other Diseases</title>
<link>https://6ix.com/company/aditxt-inc/news/aditxt-subsidiary-pearsanta-inc-engages-130000137</link>
<guid isPermaLink="true">https://6ix.com/company/aditxt-inc/news/aditxt-subsidiary-pearsanta-inc-engages-130000137</guid>
<pubDate>Tue, 29 Jul 2025 13:00:00 GMT</pubDate>
<description>MOUNTAIN VIEW, Calif., July 29, 2025--Aditxt, Inc. (Nasdaq: ADTX) ("Aditxt" or the "Company"), a social innovation platform dedicated to accelerating promising health innovations, today announced that its subsidiary, Pearsanta, Inc., ("Pearsanta") has engaged Spartan Capital Securities, LLC ("Spartan") as lead underwriter for its planned Initial Public Offering ("IPO"). This marks an important milestone in Aditxt’s Acquire, Build, and Capitalize ("ABC") strategy, which is designed to accelerate</description>
</item>
<item>
<title>Aditxt’s Subsidiary Pearsanta Receives an Invitation to Submit Full Proposal for the U.S. Department of Defense Pilot Award for the Development of its Mitomic® Ovarian Test</title>
<link>https://6ix.com/company/aditxt-inc/news/aditxt-subsidiary-pearsanta-receives-invitation-121500122</link>
<guid isPermaLink="true">https://6ix.com/company/aditxt-inc/news/aditxt-subsidiary-pearsanta-receives-invitation-121500122</guid>
<pubDate>Thu, 24 Jul 2025 12:15:00 GMT</pubDate>
<description>MOUNTAIN VIEW, Calif., July 24, 2025--Aditxt, Inc. (NASDAQ: ADTX) ("Aditxt" or the "Company"), a social innovation platform accelerating promising health innovations, is pleased to announce that its subsidiary, Pearsanta, Inc. ("Pearsanta"), has received an invitation to submit a full proposal for the Congressionally Directed Medical Research Program’s (CDMRP) Ovarian Cancer Research Program ("OCRP") Pilot Award, funded through the U.S. Department of Defense (Funding Opportunity Number: HT942525</description>
</item>
<item>
<title>Aditxt to Present at Wall Street Reporter’s Next Super Stock Livestream Today July 22, 2025, at 1 p.m. ET</title>
<link>https://6ix.com/company/aditxt-inc/news/aditxt-present-wall-street-reporter-121500292</link>
<guid isPermaLink="true">https://6ix.com/company/aditxt-inc/news/aditxt-present-wall-street-reporter-121500292</guid>
<pubDate>Tue, 22 Jul 2025 12:15:00 GMT</pubDate>
<description>MOUNTAIN VIEW, Calif., July 22, 2025--Aditxt, Inc. (Nasdaq: ADTX) ("Aditxt" or the "Company"), a social innovation platform accelerating promising health innovations, today announced a live discussion focused on its wholly owned subsidiary Adimune™, Inc. ("Adimune™"), which is advancing therapeutics designed to address autoimmune diseases.</description>
</item>
<item>
<title>Aditxt Unveils bitXbio™: A Bitcoin-Backed Treasury Strategy Designed to Accelerate Biotech Commercialization</title>
<link>https://6ix.com/company/aditxt-inc/news/aditxt-unveils-bitxbiotm-a-bitcoin-backed-treasury-strategy-designed-to-accelerate-biotech-commercialization</link>
<guid isPermaLink="true">https://6ix.com/company/aditxt-inc/news/aditxt-unveils-bitxbiotm-a-bitcoin-backed-treasury-strategy-designed-to-accelerate-biotech-commercialization</guid>
<pubDate>Mon, 07 Jul 2025 04:00:00 GMT</pubDate>
<description>Plan Combines Bitcoin Treasury Strategy and Equity Line to Support 2026 Potential Monetization Events, Starting with Pearsanta’s Planned IPO MOUNTAIN VIEW,</description>
</item>
<item>
<title>Aditxt to Present at Wall Street Reporter’s NEXT SUPER STOCK Livestream Today June 26, 2025, at 1 p.m. ET</title>
<link>https://6ix.com/company/aditxt-inc/news/aditxt-present-wall-street-reporter-121500258</link>
<guid isPermaLink="true">https://6ix.com/company/aditxt-inc/news/aditxt-present-wall-street-reporter-121500258</guid>
<pubDate>Thu, 26 Jun 2025 12:15:00 GMT</pubDate>
<description>MOUNTAIN VIEW, Calif., June 26, 2025--Aditxt, Inc. (NASDAQ: ADTX) ("Aditxt" or the "Company"), a social innovation platform accelerating promising health innovations, is pleased to announce that Co-founder and CEO Amro Albanna will be presenting at Wall Street Reporter’s NEXT SUPER STOCK livestream event on June 26, 2025 at 1:00 p.m. ET.</description>
</item>
<item>
<title>Evofem Biosciences’ CEO Saundra Pelletier Joins Aditxt Board of Directors</title>
<link>https://6ix.com/company/aditxt-inc/news/evofem-biosciences-ceo-saundra-pelletier-121500397</link>
<guid isPermaLink="true">https://6ix.com/company/aditxt-inc/news/evofem-biosciences-ceo-saundra-pelletier-121500397</guid>
<pubDate>Mon, 09 Jun 2025 12:15:00 GMT</pubDate>
<description>MOUNTAIN VIEW, Calif., June 09, 2025--Aditxt, Inc. (Nasdaq: ADTX) ("Aditxt" or the "Company"), a social innovation platform accelerating promising health innovations, today announced the appointment of Saundra Pelletier, CEO of Evofem Biosciences, Inc. (OTCPK: EVFM) ("Evofem"), to Aditxt’s Board of Directors.</description>
</item>
<item>
<title>Saundra Pelletier, Evofem Biosciences’ CEO, Dr. Friedrich Kapp, Co-CEO of Adimune, and Chris Mitton, President of Pearsanta, Will Join Aditxt Weekly Update on June 6</title>
<link>https://6ix.com/company/aditxt-inc/news/saundra-pelletier-evofem-biosciences-ceo-121500586</link>
<guid isPermaLink="true">https://6ix.com/company/aditxt-inc/news/saundra-pelletier-evofem-biosciences-ceo-121500586</guid>
<pubDate>Thu, 05 Jun 2025 12:15:00 GMT</pubDate>
<description>MOUNTAIN VIEW, Calif., June 05, 2025--Aditxt, Inc. (Nasdaq: ADTX) ("Aditxt"), a social innovation platform accelerating promising health innovations, today announced that its CEO Amro Albanna will be joined for tomorrow’s Aditxt Weekly Update by Dr. Friedrich Kapp, Chris Mitton, and Evofem Biosciences’ CEO Saundra Pelletier to discuss progress in immune therapy, early disease detection and women’s health, respectively.</description>
</item>
<item>
<title>Aditxt Announces Termination of Arrangement Agreement With Appili Therapeutics</title>
<link>https://6ix.com/company/aditxt-inc/news/aditxt-announces-termination-arrangement-agreement-120000068</link>
<guid isPermaLink="true">https://6ix.com/company/aditxt-inc/news/aditxt-announces-termination-arrangement-agreement-120000068</guid>
<pubDate>Mon, 19 May 2025 12:00:00 GMT</pubDate>
<description>MOUNTAIN VIEW, Calif., May 19, 2025--Aditxt, Inc. (NASDAQ: ADTX) ("Aditxt" or the "Company"), a social innovation platform accelerating promising health innovations, today announced that it has determined it is in the best interest of the Company and its stockholders to terminate the previously announced Arrangement Agreement with Appili Therapeutics, Inc.</description>
</item>
<item>
<title>Appili Therapeutics Provides Update on Arrangement with Aditxt, Inc.</title>
<link>https://6ix.com/company/aditxt-inc/news/appili-therapeutics-provides-update-on-arrangement-with-aditxt-inc-1</link>
<guid isPermaLink="true">https://6ix.com/company/aditxt-inc/news/appili-therapeutics-provides-update-on-arrangement-with-aditxt-inc-1</guid>
<pubDate>Mon, 19 May 2025 12:00:00 GMT</pubDate>
<description>NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES HALIFAX, Nova Scotia, May 19, 2025 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, announced that Aditxt, Inc. (“NASDAQ:ADTX”) (“Aditxt”) has delivered notice (the “Termination Notice”) purporting to terminate the arrangement agreement dat</description>
</item>
<item>
<title>Upcoming Aditxt Weekly Update to Feature Dr. Shahrokh Shabahang, Chief Innovation Officer (CIO) of Aditxt™, and Dr. Friedrich Kapp, Co-CEO of Adimune™, to Discuss Progress of Lead Therapeutic Candidate ADI-100™</title>
<link>https://6ix.com/company/aditxt-inc/news/upcoming-aditxt-weekly-feature-dr-130000528</link>
<guid isPermaLink="true">https://6ix.com/company/aditxt-inc/news/upcoming-aditxt-weekly-feature-dr-130000528</guid>
<pubDate>Fri, 02 May 2025 13:00:00 GMT</pubDate>
<description>MOUNTAIN VIEW, Calif., May 02, 2025--Aditxt, Inc. (NASDAQ: ADTX) ("Aditxt" or the "Company"), a social innovation platform accelerating promising health innovations, announced that Aditxt’s CIO Dr. Shahrokh Shabahang, and Adimune’s Co-CEO Dr. Friedrich Kapp, will join today’s Aditxt Weekly Update to discuss recent developments related to ADI-100™, the lead therapeutic candidate of its wholly owned subsidiary, Adimune.</description>
</item>
<item>
<title>Aditxt Subsidiary Pearsanta Receives IRB Approval to Initiate Clinical Study of Blood-Based Diagnostic for Endometriosis with Patient Enrollment Planned to Begin in May 2025</title>
<link>https://6ix.com/company/aditxt-inc/news/aditxt-subsidiary-pearsanta-receives-irb-121500094</link>
<guid isPermaLink="true">https://6ix.com/company/aditxt-inc/news/aditxt-subsidiary-pearsanta-receives-irb-121500094</guid>
<pubDate>Wed, 16 Apr 2025 12:15:00 GMT</pubDate>
<description>MOUNTAIN VIEW, Calif., April 16, 2025--Aditxt, Inc. (NASDAQ: ADTX) ("Aditxt" or the "Company"), a social innovation platform accelerating promising health innovations, today announced that its subsidiary, Pearsanta, Inc. ("Pearsanta"), has received Institutional Review Board (IRB) approval from WCG Clinical to initiate a prospective clinical study evaluating the Mitomic® Endometriosis Test (MET), a novel blood-based diagnostic designed to aid in the early detection of endometriosis.</description>
</item>
<item>
<title>Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials</title>
<link>https://6ix.com/company/aditxt-inc/news/aditxt-subsidiary-adimune-announces-positive-results-from-mayo-clinic-pre-clinical-studies-to-support-fda-and-european-regulatory-submissions-for-type-1-diabetes-psoriasis-and-stiff-person-syndrome-human-trials</link>
<guid isPermaLink="true">https://6ix.com/company/aditxt-inc/news/aditxt-subsidiary-adimune-announces-positive-results-from-mayo-clinic-pre-clinical-studies-to-support-fda-and-european-regulatory-submissions-for-type-1-diabetes-psoriasis-and-stiff-person-syndrome-human-trials</guid>
<pubDate>Mon, 14 Apr 2025 04:00:00 GMT</pubDate>
<description>Findings Further Support the Safety Profile and Immunomodulatory Effects of ADI-100, Adimune’s Lead Therapeutic Candidate for Autoimmune Diseases MOUNTAIN</description>
</item>
</channel>
</rss>